Shree Ganesh Remedies financials

·Pharma & HealthChart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024
845———
25.825.828.220.4
30.730.738.236.3
850———
109109109126
—+0.6%−13.7%—
35.035.039.241.8
32.0%32.0%36.1%33.2%
24.524.529.635.7
17.817.823.128.1
16.3%16.3%21.3%22.3%
₹13.84₹13.84₹17.99₹21.90
—−23.1%−17.9%—
23.823.830.7—
23.823.830.7—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹658.00

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹845 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
Market Capitalization———845.0
- Cash, Equiv & ST Investments20.428.225.825.8
+ Total Debt36.338.230.730.7
Enterprise Value———849.9
Revenue125.9108.6109.3109.3
Growth %, YoY—-13.7+0.6—
EBITDA41.839.235.035.0
Margin %33.2136.1132.0432.04
EBIT35.729.624.524.5
Net Income28.123.117.817.8
Margin %22.3321.2716.2616.26
EPS, Adj (current shares)21.9017.9913.8413.84
Growth %, YoY—-17.9-23.1—
Cash from Operations—30.723.823.8
Free Cash Flow—30.723.823.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

Shree Ganesh Remedies financials and key ratios

Figures from the company's filings with NSE

In FY26 its consolidated net profit was ₹17.8 crore on revenue of ₹109 crore. Its debt-to-equity ratio was 0.19 on 31 March 2026.

Latest balance sheet
31 March 2026

Shree Ganesh Remedies at a glance · consolidated

ROE (FY26)
11.5%ROCE 13.6%
Debt to equity
0.19net debt ₹4.8 Cr
Net worth
₹163 Cr31 March 2026
Free cash flow (FY26)
₹23.8 Cr−22.5% vs FY25
EPS (FY26)
₹13.84

Questions

Is Shree Ganesh Remedies debt free?

No. Shree Ganesh Remedies had borrowings of ₹30.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹25.9 crore, so its net debt was ₹4.8 crore.

What is the Shree Ganesh Remedies debt to equity ratio?

Shree Ganesh Remedies' debt-to-equity ratio was 0.19 on 31 March 2026: borrowings of ₹30.7 crore against total equity of ₹163 crore.

What is the Shree Ganesh Remedies book value per share?

Shree Ganesh Remedies' book value per share was ₹126.94 on 31 March 2026: shareholders' equity of ₹163 crore divided by the 1.28 crore shares in issue.

What is the Shree Ganesh Remedies net worth?

Shree Ganesh Remedies' net worth — shareholders' equity in its consolidated balance sheet — was ₹163 crore on 31 March 2026.

What is the Shree Ganesh Remedies EPS?

Shree Ganesh Remedies' basic earnings per share (EPS) were ₹13.84 in FY26, against ₹17.98 in FY25.

What is the Shree Ganesh Remedies revenue and profit in FY26?

In FY26 (April 2025–March 2026), Shree Ganesh Remedies' consolidated net profit was ₹17.8 crore, down 23.1% from ₹23.1 crore in FY25, on revenue from operations of ₹109 crore (up 0.6%).

What is the Shree Ganesh Remedies ROE and ROCE?

In FY26, Shree Ganesh Remedies' return on equity (ROE) was 11.5% and its return on capital employed (ROCE) was 13.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

How does Shree Ganesh Remedies compare with its peers?

On FY26 consolidated figures, against Jenburkt Pharmaceuticals: Shree Ganesh Remedies' operating margin of 22.5% is the lower of the two (Jenburkt Pharmaceuticals 23.8%; peer average 23.8%); its return on equity of 11.5% is the lower of the two (Jenburkt Pharmaceuticals 18.8%; peer average 18.8%).

Shree Ganesh Remedies vs Jenburkt Pharmaceuticals: how do they compare?

In FY26, Shree Ganesh Remedies earned net profit of ₹17.8 crore on revenue of ₹109 crore, against ₹34.7 crore on ₹169 crore for Jenburkt Pharmaceuticals. Shree Ganesh Remedies' operating margin was 22.5% (Jenburkt Pharmaceuticals 23.8%) and its return on equity 11.5% (Jenburkt Pharmaceuticals 18.8%).

What is the Shree Ganesh Remedies free cash flow?

In FY26, Shree Ganesh Remedies generated ₹23.8 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹23.8 crore. In FY25 it was ₹30.7 crore.

Where do these Shree Ganesh Remedies figures come from?

From Shree Ganesh Remedies' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.